$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224032154 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$18.88M	$18.80M	$9.000M
YoY Change	33.36%	108.92%	17.3%
Cost Of Revenue	$10.68M	$10.33M	$4.230M
YoY Change	38.56%	144.2%	15.09%
Gross Profit	$8.197M	$8.475M	$4.751M
YoY Change	27.15%	78.4%	18.83%
Gross Profit Margin	43.42%	45.07%	52.78%
Selling, General & Admin		$2.021M	$1.677M
YoY Change		20.56%	-2.71%
% of Gross Profit		23.85%	35.29%
Research & Development	$1.966M	$2.164M	$1.144M
YoY Change	-24.91%	89.19%	19.69%
% of Gross Profit	23.98%	25.53%	24.07%
Depreciation & Amortization	$227.4K	$322.1K	$328.3K
YoY Change	-30.52%	-1.88%	10.8%
% of Gross Profit	2.77%	3.8%	6.91%
Operating Expenses	$4.712M	$4.611M	$3.149M
YoY Change	4.22%	46.44%	5.83%
Operating Profit	$3.485M	$3.864M	$1.602M
YoY Change	80.99%	141.2%	56.65%
Interest Expense		-$3.028M	$119.4K
YoY Change		-2636.01%	-44.92%
% of Operating Profit		-78.37%	7.45%
Other Income/Expense, Net	-$13.00M	-$3.016M	-$305.3K
YoY Change	179.16%	888.1%	-57.41%
Pretax Income	-$9.519M	$847.8K	$1.297M
YoY Change	248.33%	-34.63%	323.94%
Income Tax	$1.517M	$232.0K	$155.0K
% Of Pretax Income		27.36%	11.95%
Net Earnings	-$11.04M	$615.8K	$1.142M
YoY Change	-173.9%	-46.07%	273.28%
Net Earnings / Revenue	-58.45%	3.27%	12.69%
Basic Earnings Per Share	-$0.01	$0.00	$0.00
Diluted Earnings Per Share	-$0.01	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	1.068B shares	1.068B shares	1.014B shares
Diluted Shares Outstanding	1.068B shares	1.076B shares	1.015B shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$8.407M	$9.077M
YoY Change		-7.38%	-54.11%
Cash & Equivalents	$9.999M	$8.845M	$9.077M
Short-Term Investments
Other Short-Term Assets		$435.7K	$998.1K
YoY Change		-56.35%	96.5%
Inventory	$14.16M	$13.83M	$11.17M
Prepaid Expenses
Receivables	$21.44M	$20.49M	$6.201M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$45.29M	$43.16M	$27.44M
YoY Change	30.42%	57.26%	-13.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.18M	$10.57M	$10.10M
YoY Change	4.16%	4.68%	75.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$94.24K	$21.02K
YoY Change		348.33%	-92.79%
Other Assets		$22.58M	$2.587M
YoY Change		772.78%	0.4%
Total Long-Term Assets	$42.90M	$44.69M	$19.05M
YoY Change	19.21%	134.51%	17.34%
TOTAL ASSETS
Total Short-Term Assets	$45.29M	$43.16M	$27.44M
Total Long-Term Assets	$42.90M	$44.69M	$19.05M
Total Assets	$88.20M	$87.85M	$46.50M
YoY Change	24.72%	88.92%	-3.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.983M	$2.607M	$1.875M
YoY Change	-45.05%	39.05%	16.15%
Accrued Expenses	$5.703M	$6.228M	$5.929M
YoY Change	-48.89%	5.04%	23.28%
Deferred Revenue	$12.22K	$13.33K	$13.33K
YoY Change	-8.33%	0.0%	0.0%
Short-Term Debt		$4.000M	$4.000M
YoY Change		0.0%
Long-Term Debt Due		$749.4K	$251.3K
YoY Change		198.24%	-42.23%
Total Short-Term Liabilities	$12.85M	$14.01M	$12.08M
YoY Change	-32.63%	16.04%	70.59%
LONG-TERM LIABILITIES
Long-Term Debt		$4.647M	$3.578M
YoY Change		29.86%	-72.91%
Other Long-Term Liabilities		$10.93M	$726.6K
YoY Change		1404.73%	1691.89%
Total Long-Term Liabilities	$28.08M	$15.58M	$4.305M
YoY Change	328.88%	261.92%	-72.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.85M	$14.01M	$12.08M
Total Long-Term Liabilities	$28.08M	$15.58M	$4.305M
Total Liabilities	$40.93M	$29.60M	$16.38M
YoY Change	59.73%	80.65%	-27.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.8M	-$115.8M	-$135.4M
YoY Change	5.3%	-14.47%	-3.15%
Common Stock	$1.068M	$1.068M	$1.014M
YoY Change	5.36%	5.36%	0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K	$306.8K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$47.27M	$58.25M	$30.12M
YoY Change
Total Liabilities & Shareholders Equity	$88.20M	$87.85M	$46.50M
YoY Change	24.72%	88.92%	-3.34%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$11.04M	$615.8K	$1.142M
YoY Change	-173.9%	-46.07%	273.28%
Depreciation, Depletion And Amortization	$227.4K	$322.1K	$328.3K
YoY Change	-30.52%	-1.88%	10.8%
Cash From Operating Activities		$3.144M	-$2.710M
YoY Change		-216.04%	386.05%
INVESTING ACTIVITIES
Capital Expenditures		$778.5K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$15.25K
YoY Change
Cash From Investing Activities		-$1.663M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-$174.9K	$3.957M
YoY Change		-104.42%	-66.74%
NET CHANGE
Cash From Operating Activities		$3.144M	-$2.710M
Cash From Investing Activities		-$1.663M
Cash From Financing Activities		-$174.9K	$3.957M
Net Change In Cash		$1.306M	$1.247M
YoY Change		4.72%	-88.91%
FREE CASH FLOW
Cash From Operating Activities		$3.144M	-$2.710M
Capital Expenditures		$778.5K
Free Cash Flow		$2.366M	-$2.710M
YoY Change		-187.31%	485.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	dei	Entity File Number EntityFileNumber	001-15697
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	Elite Pharmaceuticals, Inc.
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 Ludlow Avenue
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Northvale
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
CY2024Q2	dei	City Area Code CityAreaCode	(201)
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	750-2646
CY2024Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q2	dei	Trading Symbol TradingSymbol	ELTP
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2024Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion		usd
CY2023Q2	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1		usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2024Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	ELTP	Finance Directors And Officers Insurance Premium FinanceDirectorsAndOfficersInsurancePremium		usd
CY2024Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2023Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent		usd
CY2024Q2	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees		usd
CY2024Q2	ELTP	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent		pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1068273108	shares
CY2024Q2	us-gaap	Cash Cash	8407152	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	233000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	236000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20486401	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	13831318	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	435669	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	43160540	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16197891	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15906853	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10570868	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7241228	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1976049	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2222172	usd
CY2024Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	22142686	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	438222	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	94240	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	532462	usd
CY2024Q2	us-gaap	Assets Assets	87846005	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2607032	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6228095	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2024Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	115822	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	313786	usd
CY2024Q2	us-gaap	Other Loans Payable OtherLoansPayable	4000000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	319803	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416764	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	14014635	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2222	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5556	usd
CY2024Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	916747	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	2327980	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1401924	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1850656	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	9080921	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15580450	usd
CY2024Q2	us-gaap	Liabilities Liabilities	29595085	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068373108	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1068373108	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068273108	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1068273108	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1068377	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173262878	usd
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	100000	shares
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115773494	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	58250920	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87846005	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18803063	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8980076	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	10328285	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	4229521	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	8474778	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	4750555	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2163527	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1143545	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1969154	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1661704	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52329	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15000	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	425712	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	328282	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	4610722	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	3148531	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	3864056	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1602024	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2782913	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2024Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	250781	usd
CY2023Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	119412	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	5390	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	3516	usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	12000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3016304	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-305263	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	847752	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1296761	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	231979	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	154952	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	615773	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1076250204	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1014572821	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	57582818	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	615773	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52329	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	58250920	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	28960260	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	30117069	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	615773	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	1141809	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	322103	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	328282	usd
CY2024Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9810	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	133029	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5534	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	103609	usd
CY2024Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3544	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2782913	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2024Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	18209	usd
CY2024Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	52329	usd
CY2023Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	15000	usd
CY2023Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	192	usd
CY2024Q2	us-gaap	Assets Disposed Of By Method Other Than Sale In Period Of Disposition Gain Loss On Disposition1 AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1	-45599	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1042910	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3206899	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	900854	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1617715	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-286950	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-34727	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-107274	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-571885	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	926348	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	881435	usd
CY2024Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3334	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3334	usd
CY2024Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-101381	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6328	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3144463	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2709815	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	778527	usd
CY2024Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	900000	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15250	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1663277	usd
CY2023Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	4000000	usd
CY2024Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	71329	usd
CY2024Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	103577	usd
CY2023Q2	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	42777	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-174906	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3957223	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1306280	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1247408	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7539094	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8244681	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8845374	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9492089	usd
CY2024Q2	us-gaap	Interest Paid Net InterestPaidNet	222970	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	119412	usd
CY2023Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	127522	usd
CY2024Q2	ELTP	Finance Directors And Officers Insurance Premium FinanceDirectorsAndOfficersInsurancePremium	198457	usd
CY2024Q2	us-gaap	Cash Cash	8407152	usd
CY2023Q2	us-gaap	Cash Cash	9076659	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	438222	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	415430	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8845374	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9492089	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z8RElkoehmT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zR1RH2tSRLxh">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as reported amounts of revenues and expenses during the reporting period. Such management estimates and assumptions include, but are not limited to, standalone selling price for each distinct performance obligation included in customer contracts with multiple performance obligations, the period of benefit for deferred commissions, valuation of intangible assets, the useful life of property and equipment and identifiable intangible assets, stock-based compensation expense and income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	438222	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	432832	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
CY2024Q2	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	900000	usd
CY2024Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7241228	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6341228	usd
CY2024	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	0	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6341228	usd
CY2024Q2	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	615773	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1141809	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	615773	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1141809	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1068273108	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013915081	shares
CY2024Q2	us-gaap	Dilutive Securities DilutiveSecurities	7977096	usd
CY2023Q2	us-gaap	Dilutive Securities DilutiveSecurities	657740	usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1076250204	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1014572821	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	6298008	usd
CY2024Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2782913	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	9080921	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	521711	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-189367	usd
CY2023Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	711078	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4264775	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4465970	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2260532	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1804426	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	7306011	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	6660068	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	13831318	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12930464	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26768759	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26082146	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16197891	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15906853	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10570868	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10175293	usd
CY2024Q2	us-gaap	Depreciation Depreciation	322103	usd
CY2023Q2	us-gaap	Depreciation Depreciation	328282	usd
CY2024Q2	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit	4435536	usd
CY2024Q1	ELTP	Accrued Codevelopment Profit Split AccruedCodevelopmentProfitSplit	3684587	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	699097	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	485327	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	370869	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	206225	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	324265	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	668108	usd
CY2024Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	165000	usd
CY2024Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	90000	usd
CY2024Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	160828	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	50000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	125000	usd
CY2024Q2	ELTP	Accrued Director Dues AccruedDirectorDues	22500	usd
CY2024Q1	ELTP	Accrued Director Dues AccruedDirectorDues	22500	usd
CY2024Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	20000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6228095	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5301747	usd
CY2024Q2	ELTP	Mortgage Loan Payable MortgageLoanPayable	2397969	usd
CY2024Q1	ELTP	Mortgage Loan Payable MortgageLoanPayable	2418426	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	243797	usd
CY2024Q1	us-gaap	Loans Payable LoansPayable	128460	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	313786	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	180399	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	2327980	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	2366487	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	34883	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	77238	usd
CY2024Q2	us-gaap	Lessee Finance Lease Description LesseeFinanceLeaseDescription	(i) ownership of the underlying asset transfers to the Company by the end of the lease term; (ii) the lease contains an option to purchase the underlying asset that the Company is reasonably expected to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of lease payments and any residual value guaranteed by the Company equals or exceeds substantially all of the fair value of the underlying asset; or (v) the underlying asset is of a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1976049	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2079658	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2222172	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2355201	usd
CY2024Q2	ELTP	Lease Assets LeaseAssets	4198221	usd
CY2024Q1	ELTP	Lease Assets LeaseAssets	4434859	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	319803	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	312739	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	416764	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	411418	usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1401924	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1480317	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1850656	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1957383	usd
CY2024Q2	ELTP	Lease Liabilities LeaseLiabilities	3989147	usd
CY2024Q1	ELTP	Lease Liabilities LeaseLiabilities	4161857	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	469677	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due In Next Rolling Twelve Months FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths	352565	usd
CY2024Q2	ELTP	Lease Liability Payments Due Next Twelve Months LeaseLiabilityPaymentsDueNextTwelveMonths	822242	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	623565	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	468391	usd
CY2024Q2	ELTP	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	1091956	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	637050	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	449745	usd
CY2024Q2	ELTP	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	1086795	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	650871	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	449745	usd
CY2024Q2	ELTP	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	1100616	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	440159	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	408453	usd
CY2024Q2	ELTP	Lease Liability Payments Due Year Five LeaseLiabilityPaymentsDueYearFive	848612	usd
CY2024Q2	ELTP	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	6340	usd
CY2024Q2	ELTP	Lease Liability Payments Due After Year Four LeaseLiabilityPaymentsDueAfterYearFour	6340	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	553899	usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	413515	usd
CY2024Q2	ELTP	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	967414	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2267423	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	1721724	usd
CY2024Q2	ELTP	Lease Liabilities LeaseLiabilities	3989147	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M18D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.095	pure
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y9M18D
CY2024Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y1M6D
CY2024Q3	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	12730000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15730000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1626748	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15730000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.05
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2319442	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4050000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.04
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	633054	usd
CY2024Q2	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.20
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	385592	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y11M8D
CY2024Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	231979	usd
CY2023Q2	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	154975	usd
CY2024Q2	ELTP	Income Tax Expense Percentage IncomeTaxExpensePercentage	0.274	pure
CY2023Q2	ELTP	Income Tax Expense Percentage IncomeTaxExpensePercentage	0.119	pure
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-032154-index-headers.html	Edgar Link	pending
0001493152-24-032154-index.html	Edgar Link	pending
0001493152-24-032154.txt	Edgar Link	pending
0001493152-24-032154-xbrl.zip	Edgar Link	pending
eltp-20240630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
eltp-20240630_cal.xml	Edgar Link	unprocessable
eltp-20240630_lab.xml	Edgar Link	unprocessable
eltp-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
eltp-20240630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q3 Form 10-Q Financial Statement

#000149315224032154 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2024 Q3 Form 10-Q Financial Statement

#000149315224032154 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp